These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27137719)

  • 1. Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.
    Gosselin NH; Mouksassi MS; Lu JF; Hsu CP
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):463-72. PubMed ID: 27137719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
    Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
    Lorusso P; Heath EI; McGreivy J; Sun YN; Melara R; Yan L; Malburg L; Ingram M; Wiezorek J; Chen L; Pilat MJ
    Invest New Drugs; 2008 Oct; 26(5):455-62. PubMed ID: 18574557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
    Ezzeldin E; Iqbal M; Al-Salahi R; El-Nahhas T
    J Pharm Biomed Anal; 2019 Mar; 166():244-251. PubMed ID: 30665192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
    Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
    Price TJ; Lipton L; McGreivy J; McCoy S; Sun YN; Rosenthal MA
    Br J Cancer; 2008 Nov; 99(9):1387-94. PubMed ID: 18971935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
    De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA
    Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
    Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
    Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE; Bello CL; Kang D; Amantea M
    Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.
    Rho CR; Kang S; Park KC; Yang KJ; Choi H; Cho WK
    J Ocul Pharmacol Ther; 2015 Feb; 31(1):25-31. PubMed ID: 25255037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of axitinib in healthy volunteers.
    Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
    Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
    Tebbutt N; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Warner DJ; Chen L; Hsu CP; Goldstein D
    Cancer Chemother Pharmacol; 2015 May; 75(5):993-1004. PubMed ID: 25772756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
    Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.
    Rosen LS; Lipton L; Price TJ; Belman ND; Boccia RV; Hurwitz HI; Stephenson JJ; Wirth LJ; McCoy S; Hei YJ; Hsu CP; Tebbutt NC
    BMC Cancer; 2013 May; 13():242. PubMed ID: 23679351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.